December 17, 2015 - 1:06 a.m.
Galapagos and Gilead Announce Global Partnership to Develop Filgotinib for the Treatment of Rheumatoid Arthritis and Other Inflammatory Diseases
Printer Friendly Version 
December 08, 2015 - 7:30 a.m.
Phase 3 Results for Zydelig® With Bendamustine and Rituximab for Relapsed Chronic Lymphocytic Leukemia (CLL) Presented at American Society of Hematology Annual Meeting
Printer Friendly Version 
December 04, 2015 - 5:29 a.m.
European Medicines Agency Validates Gilead’s Marketing Application for Fixed-Dose Combination of Sofosbuvir/Velpatasvir for the Treatment of Hepatitis C
Printer Friendly Version 
November 24, 2015 - 5:01 p.m.
Gilead Sciences to Present at Two Upcoming Investor Conferences on Tuesday, December 1
Printer Friendly Version 
November 23, 2015 - 6:36 a.m.
European Commission Grants Marketing Authorization for Gilead’s Single Tablet Regimen Genvoya® (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide) for the Treatment of HIV-1 Infection
Printer Friendly Version 
November 16, 2015 - 9:01 a.m.
Gilead’s Zydelig® Combined with Bendamustine and Rituximab Shows Superior Efficacy to Bendamustine/Rituximab in Phase 3 Study of Patients with Relapsed Chronic Lymphocytic Leukemia
Printer Friendly Version 
November 14, 2015 - 9:03 a.m.
Gilead Presents New Data at The Liver Meeting 2015
Printer Friendly Version 
November 14, 2015 - 9:03 a.m.
Multiple Scientific Presentations at The Liver Meeting 2015 Further Highlight the Utility of Sofosbuvir-Based Hepatitis C Therapies
Printer Friendly Version 
November 12, 2015 - 5:55 p.m.
U.S. FDA Approves New Indications for Harvoni®, Gilead’s Once-Daily Single Tablet Regimen for Chronic Hepatitis C
Printer Friendly Version 
November 09, 2015 - 8:32 a.m.
Gilead Sciences to Present at the Credit Suisse 24th Annual Healthcare Conference on Tuesday, November 10
Printer Friendly Version 
November 05, 2015 - 12:48 p.m.
U.S. Food and Drug Administration Approves Gilead’s Single Tablet Regimen Genvoya® (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide) for Treatment of HIV-1 Infection
Printer Friendly Version 
October 28, 2015 - 5:53 p.m.
Gilead Submits New Drug Application to U.S. Food and Drug Administration for Fixed-Dose Combination of Sofosbuvir/Velpatasvir for Treatment of All Six Genotypes of Hepatitis C
Printer Friendly Version 
October 27, 2015 - 4:01 p.m.
Gilead Sciences Announces Third Quarter 2015 Financial Results
Printer Friendly Version 
October 27, 2015 - 4:01 p.m.
Gilead Sciences Announces Fourth Quarter 2015 Dividend
Printer Friendly Version 
October 22, 2015 - 7:34 a.m.
Gilead Announces Phase 3 Results for Genvoya® (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide), an Investigational Once-Daily Single Tablet Regimen for HIV
Printer Friendly Version 
October 21, 2015 - 10:02 a.m.
Gilead Provides Update on Investigational Compound, GS-5734, for the Treatment of Ebola Virus Disease
Printer Friendly Version 
October 20, 2015 - 5:01 p.m.
Gilead Sciences to Release Third Quarter 2015 Financial Results on Tuesday, October 27, 2015
Printer Friendly Version 
October 02, 2015 - 6:20 p.m.
U.S. Food and Drug Administration Approves New Treatment Combination of Gilead’s Letairis® with Tadalafil for Pulmonary Arterial Hypertension (WHO Group 1)
Printer Friendly Version 
September 25, 2015 - 7:35 a.m.
European CHMP Adopts Positive Opinion for Gilead’s Single Tablet Regimen Genvoya® (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide) for the Treatment of HIV
Printer Friendly Version 
September 21, 2015 - 8:32 a.m.
Gilead Announces SVR12 Rates from Four Phase 3 Studies Evaluating a Once-Daily, Fixed-Dose Combination of Sofosbuvir (SOF) and Velpatasvir (VEL) (GS-5816) for the Treatment of All Six Hepatitis C Genotypes
Printer Friendly Version 
September 15, 2015 - 5:00 p.m.
Gilead Sciences to Present at the Morgan Stanley Global Healthcare Conference on Wednesday, September 16
Printer Friendly Version 
September 09, 2015 - 8:58 p.m.
Gilead Prices $10 Billion of Senior Unsecured Notes
Printer Friendly Version 
September 08, 2015 - 5:01 p.m.
Gilead Sciences to Present at the Baird 2015 Healthcare Conference on Wednesday, September 9
Printer Friendly Version 
September 02, 2015 - 8:31 a.m.
Gilead’s Investigational Fixed-Dose Combination of Emtricitabine/Tenofovir Alafenamide (F/TAF) Meets Primary 48-Week Objective in Phase 3 Study
Printer Friendly Version 
August 26, 2015 - 5:01 p.m.
Results From the AMBITION Study of First-Line Treatment With Letairis and Tadalafil in Pulmonary Arterial Hypertension Published in The New England Journal of Medicine
Printer Friendly Version 
August 20, 2015 - 4:32 p.m.
European Medicines Agency Validates Gilead’s Marketing Application for Single Tablet Regimen Containing Rilpivirine, Emtricitabine and Tenofovir Alafenamide (R/F/TAF) for HIV Treatment
Printer Friendly Version 
July 28, 2015 - 4:04 p.m.
Gilead Sciences Announces Third Quarter 2015 Dividend
Printer Friendly Version 
July 28, 2015 - 4:02 p.m.
Gilead Sciences Announces Second Quarter 2015 Financial Results
Printer Friendly Version 
July 27, 2015 - 4:31 p.m.
Gilead Announces Executive Promotions
Printer Friendly Version 
July 21, 2015 - 5:01 p.m.
Gilead Sciences to Release Second Quarter 2015 Financial Results on Tuesday, July 28, 2015
Printer Friendly Version 
July 21, 2015 - 2:08 p.m.
Gilead Announces Phase 3 Results From the First Study to Evaluate Switching From TDF-Based Regimens to a TAF-Based Regimen Containing Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide (E/C/F/TAF)
Printer Friendly Version 
July 03, 2015 - 2:02 a.m.
Japan’s Ministry of Health, Labour and Welfare Approves Gilead’s Harvoni®, the First Once-Daily Single Tablet Regimen for the Treatment of Genotype 1 Chronic Hepatitis C
Printer Friendly Version 
July 01, 2015 - 4:31 p.m.
Gilead Submits New Drug Application to U.S. Food and Drug Administration for Single Tablet Regimen for HIV Containing Rilpivirine, Emtricitabine and Tenofovir Alafenamide (R/F/TAF)
Printer Friendly Version 
June 08, 2015 - 5:01 p.m.
Gilead Sciences to Present at Two Upcoming Investor Conferences on Tuesday, June 9
Printer Friendly Version 
May 31, 2015 - 9:01 a.m.
Zydelig® in Combination With Ofatumumab Improves Progression-Free Survival in Previously-Treated Patients With Chronic Lymphocytic Leukemia
Printer Friendly Version 
May 28, 2015 - 8:31 a.m.
European Medicines Agency Validates Gilead’s Marketing Application for Fixed-Dose Combination of Emtricitabine and Tenofovir Alafenamide for HIV Treatment
Printer Friendly Version 
May 27, 2015 - 5:01 p.m.
Gilead Sciences to Present at the Bernstein 31st Annual Strategic Decisions Conference on Thursday, May 28
Printer Friendly Version 
May 18, 2015 - 5:00 p.m.
Gilead Sciences to Present at the UBS 2015 Global Healthcare Conference on Tuesday, May 19
Printer Friendly Version 
May 12, 2015 - 5:01 p.m.
Gilead Sciences to Present at the Bank of America Merrill Lynch 2015 Health Care Conference on Wednesday, May 13
Printer Friendly Version 
May 06, 2015 - 8:32 a.m.
Gilead Sciences Acquires EpiTherapeutics
Printer Friendly Version 
April 30, 2015 - 4:03 p.m.
Gilead Sciences Declares First Quarterly Cash Dividend
Printer Friendly Version 
April 30, 2015 - 4:02 p.m.
Gilead Sciences Announces First Quarter 2015 Financial Results
Printer Friendly Version 
April 25, 2015 - 1:01 a.m.
Gilead Announces Results From Studies Evaluating Sofosbuvir-Based Regimens in Chronic Hepatitis C Patients With Genotypes 2-5
Printer Friendly Version 
April 23, 2015 - 5:02 p.m.
Gilead Sciences to Release First Quarter 2015 Financial Results on Thursday, April 30, 2015
Printer Friendly Version 
April 23, 2015 - 1:01 a.m.
Gilead’s Harvoni and Sovaldi Demonstrate Efficacy and Safety among Chronic Hepatitis C Patients with Advanced Liver Disease
Printer Friendly Version 
April 23, 2015 - 1:01 a.m.
Gilead Announces Data for Investigational, All-Oral, Pan-Genotypic Three-Drug Regimen of Sofosbuvir, GS-5816 and GS-9857 for Chronic Hepatitis C
Printer Friendly Version 
April 07, 2015 - 5:57 p.m.
Gilead Submits New Drug Application to U.S. Food and Drug Administration for Fixed-Dose Combination of Emtricitabine/Tenofovir Alafenamide for HIV Treatment
Printer Friendly Version 
March 26, 2015 - 2:00 a.m.
Japan’s Ministry of Health, Labour and Welfare Approves Gilead’s Sovaldi® (sofosbuvir) for the Treatment of Genotype 2 Chronic Hepatitis C
Printer Friendly Version 
March 10, 2015 - 5:00 p.m.
Gilead Sciences to Present at the Barclays Global Healthcare Conference on Wednesday, March 11
Printer Friendly Version 
March 02, 2015 - 5:00 p.m.
Gilead Sciences to Present at the Cowen and Company 35th Annual Health Care Conference on Tuesday, March 3
Printer Friendly Version 
February 26, 2015 - 7:06 p.m.
Gilead Announces Phase 3 Results for Investigational Once-Daily Single Tablet HIV Regimen Containing Tenofovir Alafenamide (TAF)
Printer Friendly Version 
February 26, 2015 - 3:16 p.m.
Gilead Announces SVR12 Rates From Phase 3 Study Evaluating Harvoni® for the Treatment of Chronic Hepatitis C in Patients Co-Infected With HIV
Printer Friendly Version 
February 25, 2015 - 3:27 p.m.
Gilead Announces Preclinical Data for an Investigational TLR7 Agonist in SIV-Infected, Virally Suppressed Monkeys
Printer Friendly Version 
February 24, 2015 - 5:02 p.m.
Gilead Sciences to Present at the RBC Capital Markets 2015 Healthcare Conference on Wednesday, February 25
Printer Friendly Version 
February 09, 2015 - 5:01 p.m.
Gilead Sciences to Present at Two Upcoming Investor Conferences
Printer Friendly Version 
February 03, 2015 - 4:07 p.m.
Gilead Sciences Announces 43 Cents Quarterly Dividend Program and $15 Billion Share Buyback Program
Printer Friendly Version 
February 03, 2015 - 4:07 p.m.
Gilead Sciences Announces Fourth Quarter and Full Year 2014 Financial Results
Printer Friendly Version 
January 28, 2015 - 4:31 p.m.
Gilead Announces Executive Promotions
Printer Friendly Version 
January 27, 2015 - 5:01 p.m.
Gilead Sciences to Release Fourth Quarter and Full Year 2014 Financial Results on Tuesday, February 3, 2015
Printer Friendly Version 
January 26, 2015 - 1:01 a.m.
Gilead Expands Hepatitis C Generic Licensing Agreements to Include Investigational Pan-Genotypic Agent
Printer Friendly Version 
January 12, 2015 - 5:01 p.m.
Gilead Sciences to Present at the 33rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 13
Printer Friendly Version 
January 06, 2015 - 8:31 a.m.
Gilead Sciences Announces Acquisition of Phenex Pharmaceuticals’ Development Program for Non-Alcoholic Steatohepatitis (NASH) and Other Liver Diseases
Printer Friendly Version 
NASDAQ (US Dollar)
$78.94
 Stock is Down 1.69 (2.08%)
Data as of 09/27/16 12:49 p.m. ET
Minimum 20 minute delay
Refresh Quote